London-based AstraZeneca will face a Sept. 2012 trial over a lawsuit filed by Arkansas Attorney General Dustin McDaniel. State officials claim the pharmaceutical company defrauded the state's Medicaid program by failing to outline a drug's risks, according to a Bloomberg report.
The anti-psychotic drug, Seroquel, has been the source of legal problems for the drugmaker over the past year. In March, AstraZeneca agreed to pay $68.5 million to resolve claims of off-label marketing in several states.
Arkansas officials opted out of the March settlement. The state now seeks a $5,000 penalty for each Seroquel written in Arkansas over an 11-year period beginning in 1997. Seroquel was the company's second-largest selling drug in 2009.
AstraZeneca officials have said the drugmaker will be "fully vindicated as the case progresses," according to the news report.
Read the Bloomberg report on AstraZeneca and Arkansas.
Novo Nordisk Agrees to Pay $1.7M to Settle Kickback Allegations
UCB Pleads Guilty to Off-Label Marketing of Epilepsy Drug; Will Pay $34M
The anti-psychotic drug, Seroquel, has been the source of legal problems for the drugmaker over the past year. In March, AstraZeneca agreed to pay $68.5 million to resolve claims of off-label marketing in several states.
Arkansas officials opted out of the March settlement. The state now seeks a $5,000 penalty for each Seroquel written in Arkansas over an 11-year period beginning in 1997. Seroquel was the company's second-largest selling drug in 2009.
AstraZeneca officials have said the drugmaker will be "fully vindicated as the case progresses," according to the news report.
Read the Bloomberg report on AstraZeneca and Arkansas.
Related Articles on Pharmaceutical Fraud:
Supreme Court Rejects Appeal to Revive Class-Action Suit Against Eli LillyNovo Nordisk Agrees to Pay $1.7M to Settle Kickback Allegations
UCB Pleads Guilty to Off-Label Marketing of Epilepsy Drug; Will Pay $34M